Baidu
map

npj Primary Care Respiratory Medicine:患者角度的过敏性鼻炎网络定性调查

2019-10-02 AlexYang MedSci原创

患者对非处方药物进行自我选择来对过敏性鼻炎进行治疗不是最优的选择。对过敏性鼻炎网络的绘制阐释了患者多过敏性鼻炎的自我治疗最多能够受到11个个体/资源(变量)的影响。最近,有研究人员见顶了过敏性鼻炎网络中的变量情况并鉴定了影响患者感受程度的因子。他们的研究是在实证框架和社会网络理论下的定性探索名,并对变应性鼻炎患者进行网络访谈,还对其转录本进行演绎和归纳分析。转录本通过研究者单独进行编码并进行讨论达

患者对非处方药物进行自我选择来对过敏性鼻炎进行治疗不是最优的选择。对过敏性鼻炎网络的绘制阐释了患者多过敏性鼻炎的自我治疗最多能够受到11个个体/资源(变量)的影响。

最近,有研究人员见顶了过敏性鼻炎网络中的变量情况并鉴定了影响患者感受程度的因子。他们的研究是在实证框架和社会网络理论下的定性探索名,并对变应性鼻炎患者进行网络访谈,还对其转录本进行演绎和归纳分析。转录本通过研究者单独进行编码并进行讨论达到意见一致。研究发现,41名参与者描述了17个影响他们进行过敏性鼻炎治疗的变量并阐释了这些变量的角色。这些变量可以分成5类:诊断、药物处方/供应/管理、药物推荐、关于变应性鼻炎的信息和情感支持。参与者与这些变量的互作经常是急性的且具有长期的影响,且参与者经常长期进行自我管理。每个变量对过敏性鼻炎的影响的意义依赖于对其的信任程度以及对参与者变应性鼻炎日常管理和/或参与者信念的影响。

最后,研究人员中指出,过敏性鼻炎的管理是分散的,可以通过开发策略、资源和政策来支持自我管理与患者和健康专业人士相结合来进行自我管理的改善。

原始出处:

Biljana Cvetkovski, Vicky Kritikos, Rachel Tan et al. A qualitative investigation of the allergic rhinitis network from the perspective of the patient. npj Primary Care Respiratory Medicine. 19 Sep 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1858994, encodeId=48201858994df, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Dec 07 02:09:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047164, encodeId=5b76204e16410, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 15 22:09:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791473, encodeId=8d621e91473e6, content=<a href='/topic/show?id=d883146e4b0' target=_blank style='color:#2F92EE;'>#PRIMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14674, encryptionId=d883146e4b0, topicName=PRIMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Feb 26 09:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036274, encodeId=007f20362e47a, content=<a href='/topic/show?id=0526146e530' target=_blank style='color:#2F92EE;'>#primary#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14675, encryptionId=0526146e530, topicName=primary)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Thu Feb 13 14:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773816, encodeId=1cbe1e7381607, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 17 19:09:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577688, encodeId=193915e76889a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610013, encodeId=cef41610013a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]
    2019-12-07 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1858994, encodeId=48201858994df, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Dec 07 02:09:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047164, encodeId=5b76204e16410, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 15 22:09:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791473, encodeId=8d621e91473e6, content=<a href='/topic/show?id=d883146e4b0' target=_blank style='color:#2F92EE;'>#PRIMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14674, encryptionId=d883146e4b0, topicName=PRIMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Feb 26 09:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036274, encodeId=007f20362e47a, content=<a href='/topic/show?id=0526146e530' target=_blank style='color:#2F92EE;'>#primary#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14675, encryptionId=0526146e530, topicName=primary)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Thu Feb 13 14:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773816, encodeId=1cbe1e7381607, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 17 19:09:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577688, encodeId=193915e76889a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610013, encodeId=cef41610013a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1858994, encodeId=48201858994df, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Dec 07 02:09:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047164, encodeId=5b76204e16410, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 15 22:09:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791473, encodeId=8d621e91473e6, content=<a href='/topic/show?id=d883146e4b0' target=_blank style='color:#2F92EE;'>#PRIMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14674, encryptionId=d883146e4b0, topicName=PRIMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Feb 26 09:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036274, encodeId=007f20362e47a, content=<a href='/topic/show?id=0526146e530' target=_blank style='color:#2F92EE;'>#primary#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14675, encryptionId=0526146e530, topicName=primary)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Thu Feb 13 14:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773816, encodeId=1cbe1e7381607, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 17 19:09:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577688, encodeId=193915e76889a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610013, encodeId=cef41610013a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]
    2020-02-26 ssnine
  4. [GetPortalCommentsPageByObjectIdResponse(id=1858994, encodeId=48201858994df, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Dec 07 02:09:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047164, encodeId=5b76204e16410, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 15 22:09:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791473, encodeId=8d621e91473e6, content=<a href='/topic/show?id=d883146e4b0' target=_blank style='color:#2F92EE;'>#PRIMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14674, encryptionId=d883146e4b0, topicName=PRIMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Feb 26 09:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036274, encodeId=007f20362e47a, content=<a href='/topic/show?id=0526146e530' target=_blank style='color:#2F92EE;'>#primary#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14675, encryptionId=0526146e530, topicName=primary)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Thu Feb 13 14:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773816, encodeId=1cbe1e7381607, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 17 19:09:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577688, encodeId=193915e76889a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610013, encodeId=cef41610013a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]
    2020-02-13 mnda
  5. [GetPortalCommentsPageByObjectIdResponse(id=1858994, encodeId=48201858994df, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Dec 07 02:09:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047164, encodeId=5b76204e16410, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 15 22:09:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791473, encodeId=8d621e91473e6, content=<a href='/topic/show?id=d883146e4b0' target=_blank style='color:#2F92EE;'>#PRIMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14674, encryptionId=d883146e4b0, topicName=PRIMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Feb 26 09:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036274, encodeId=007f20362e47a, content=<a href='/topic/show?id=0526146e530' target=_blank style='color:#2F92EE;'>#primary#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14675, encryptionId=0526146e530, topicName=primary)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Thu Feb 13 14:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773816, encodeId=1cbe1e7381607, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 17 19:09:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577688, encodeId=193915e76889a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610013, encodeId=cef41610013a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]
    2020-08-17 kalseyzl
  6. [GetPortalCommentsPageByObjectIdResponse(id=1858994, encodeId=48201858994df, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Dec 07 02:09:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047164, encodeId=5b76204e16410, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 15 22:09:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791473, encodeId=8d621e91473e6, content=<a href='/topic/show?id=d883146e4b0' target=_blank style='color:#2F92EE;'>#PRIMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14674, encryptionId=d883146e4b0, topicName=PRIMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Feb 26 09:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036274, encodeId=007f20362e47a, content=<a href='/topic/show?id=0526146e530' target=_blank style='color:#2F92EE;'>#primary#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14675, encryptionId=0526146e530, topicName=primary)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Thu Feb 13 14:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773816, encodeId=1cbe1e7381607, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 17 19:09:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577688, encodeId=193915e76889a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610013, encodeId=cef41610013a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1858994, encodeId=48201858994df, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Sat Dec 07 02:09:00 CST 2019, time=2019-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047164, encodeId=5b76204e16410, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri May 15 22:09:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1791473, encodeId=8d621e91473e6, content=<a href='/topic/show?id=d883146e4b0' target=_blank style='color:#2F92EE;'>#PRIMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14674, encryptionId=d883146e4b0, topicName=PRIMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25c8396, createdName=ssnine, createdTime=Wed Feb 26 09:09:00 CST 2020, time=2020-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036274, encodeId=007f20362e47a, content=<a href='/topic/show?id=0526146e530' target=_blank style='color:#2F92EE;'>#primary#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14675, encryptionId=0526146e530, topicName=primary)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a8d381, createdName=mnda, createdTime=Thu Feb 13 14:09:00 CST 2020, time=2020-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773816, encodeId=1cbe1e7381607, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Aug 17 19:09:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577688, encodeId=193915e76889a, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610013, encodeId=cef41610013a4, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Oct 04 13:09:00 CST 2019, time=2019-10-04, status=1, ipAttribution=)]

相关资讯

Am J Otolaryngol:过敏性鼻炎患者的集群免疫治疗和常规免疫治疗的副作用事件比较研究

过敏原特异性免疫治疗(AIT)的集群治疗是过敏性鼻炎(AR)患者的高性价比疗法,但是由于每次治疗时使用的剂量比传统免疫疗法更大,其安全性仍旧存在质疑。是否集群疗法能够导致更高风险的副作用仍旧是一个问题。最近,有研究人员调查了是否集群疗法比常规疗法导致局部副作用(LARs)和全身副作用(SARs)更高的风险。研究人员搜索了相关的数据库对集群和常规疗法进行了比较,并对与副作用事件相关的5个研究结果进行

J Res Med Sci:免疫治疗过敏性鼻炎患者共生素治疗能够显著的降低白介素-17的表达

过敏性鼻炎(AR)是世界范围内最常见的过敏性比疾病。最近,有研究人员在一个安慰剂对照试验中,评估了共生素在接受了免疫治疗的AR患者中对干扰素-γ(IFN-γ)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、白细胞介素-17(IL-17)、转化生长因子β(TGF-β)、叉头盒P3(FoxP 3)表达的影响。研究包括了20名AR患者,并随机分配到共生素组和安慰剂对照组,他们已经接受了为期

Rhinology:泛福舒能够通过改善Th1/Th2细胞因子平衡减轻永久过敏性鼻炎

益生菌主要分布在粘膜系统且能够增强粘膜障碍功能和调控免疫响应。泛福舒(BV)是一种益生菌,已经用于呼吸道感染患者的治疗,但是对过敏性鼻炎可能的效果仍旧没有评估。最近,有研究人员调查了BV在永久AR患者中的临床疗效,并阐释了潜在的细胞学机制。研究包括了60名AR患者,并随机分到BV组(n=30)和安慰剂组(n=30)。研究发现,BV治疗后,BV组的药物得分与安慰剂组相比显著减少,并且总鼻症状得分和个

秋季过敏性鼻炎高发,美中宜和专家支招如何防御

秋季是过敏性鼻炎高发的季节。近日,美中宜和耳鼻喉科专家、副主任医师刘勇刚就过敏性鼻炎的成因、症状以及控制预防等问题进行了深度解答。秋季是过敏性鼻炎高发的季节。近日,美中宜和耳鼻喉科专家、副主任医师刘勇刚就过敏性鼻炎的成因、症状以及控制预防等问题进行了深度解答。过敏性鼻炎是一种发生在鼻部的过敏性的疾病,跟接触变应原有关,因此又叫变应性鼻炎。它的症状有很多,主要是鼻塞、流清鼻涕、打喷嚏、鼻痒。听起来是

Chest:高海拔儿童的过敏性鼻炎与阻塞性睡眠呼吸暂停

由此可见,在高海拔地区有症状的AR儿童中,AR严重程度增加与更严重的OSA有关。

Mol Immunol:Madi-Ryuk的抗炎症作用和其活性鞣酸对过敏性鼻炎的影响研究

Madi-Ryuk(MDR)是韩国的一种传统药物,广泛的用于治疗关节炎,并且之前研究人员在体外小鼠模型中报道了MDR的抗过敏性炎症的作用。然而,MDR在体内过敏性炎症反应中的治疗证据还没有被阐释。最近,有研究人员调查了MDR和其活性鞣酸成分(TA)在卵清蛋白(OVA)诱导的AR小鼠模型中的效果。OVA挑战的AR小鼠口服MDR或者其有效组分TA,共进行10天。研究发现,在具有AR的小鼠中,MDR和T

Baidu
map
Baidu
map
Baidu
map